|
|
| Product Name: | KDU691 | | Synonyms: | KDU691;KDU691;KDU-691;KDU 691;1513879-19-0;KDU691 >=98% (HPLC);Imidazo[1,2-a]pyrazine-6-carboxamide, N-(4-chlorophenyl)-N-methyl-3-[4-[(methylamino)carbonyl]phenyl]-;PI4 kinases,blood,Inhibitor,liver,Phosphatidylinositol 4 kinases,ring-stage,falciparum,Parasite,plasmodium,schizonts,gametocytes,KDU 691,PI4K,KDU-691,inhibit,KDU691,stage | | CAS: | 1513879-19-0 | | MF: | C22H18ClN5O2 | | MW: | 419.86 | | EINECS: | | | Product Categories: | | | Mol File: | 1513879-19-0.mol |  |
| | KDU691 Chemical Properties |
| density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:PBS (pH 7.2) (1:9):0.1(Max Conc. mg/mL);0.24(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);23.82(Max Conc. mM) | | form | A crystalline solid | | pka | 14.59±0.46(Predicted) |
| | KDU691 Usage And Synthesis |
| Description | KDU691 is an antimalarial compound. It inhibits recombinant P. vivax phosphatidylinositol 4-kinase (PI4K) with an IC50 value of 1.5 nM. KDU691 is selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -γ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 μM, respectively), as well as VPS34 (IC50 = >9.7 μM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 μM). It is active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 μM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 μM, respectively). KDU691 completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys when administered at a dose of 20 mg/kg. | | Uses | KDU691, is a PI4K inhibitor. |
| | KDU691 Preparation Products And Raw materials |
|